FGH10019 (C09-1133-752)

FGH10019 is a novel sterol regulatory element-binding protein ( SREBP ) inhibitor with IC 50 of 1 μM.In VitroTreatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC 50 of analog FGH10019 is approximately 1 μM, which is 5-10 times lower than the IC 50 of fatostatin (appr 10 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoFGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 1 μM (SREBP). Specification: 0.99 Molecular Formula: C18H19N3O2S2 Molecular Weight: 373.49 PubChem CID: 25012898 Isomeric SMILES: CCCC1=NC=CC(=C1)C2=NC(=CS2)C3=CC=C(C=C3)NS(=O)(=O)C